Intra-Arterial Gemcitabine Extends PFS in Locally Advanced Pancreatic Cancer

Logo - Healio

Intra-arterial administration of gemcitabine conferred a median PFS benefit of 8 months when compared with standard of care for patients with locally advanced pancreatic cancer, according to results of the phase 3 TiGeR-PaC study.

The findings, presented during ESMO World Congress on Gastrointestinal Cancer, also showed a 6-month median OS benefit with intra-arterial administration of gemcitabine (RenovoGem, RenovoRx) vs. systemic chemotherapy, according to a press release from the agent’s manufacturer.

View the entire article on

Previous Post
Intra-arterial Gemcitabine Improves OS in Locally Advanced Pancreatic Cancer
Next Post
Survival Benefit Shown With IA Gemcitabine in Patients with Locally Advanced Pancreatic Cancer